Drug Type Hormone |
Synonyms- |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | - | - | |
Neurocognitive Disorders | Phase 2 | - | - |
Not Applicable | 244 | ctqcjguswt(iouhzejrba) = 13 (5.3%) were discontinued due to adverse events dcmzzkuqsd (xoaovuhnfa ) | - | 17 Dec 2022 | |||
Placebo | |||||||
Phase 1/2 | 21 | (Insulin, Intranasal) | gjdndwrbgp(vhdveakvrm) = mteeovopmy puxedyrhhv (pucmkocmfd, ppgissyqhw - grcardqepg) View more | - | 07 Jul 2021 | ||
Placebo, intranasal (Placebo, Intranasal) | gjdndwrbgp(vhdveakvrm) = qvimwfwxnp puxedyrhhv (pucmkocmfd, qqcpchjdve - yejfkamswl) View more | ||||||
Phase 2 | 15 | (Insulin) | dwonxfsgut(gvruawqthf) = uodysmqcmb qnydkwfhof (tcxpwhoyqv, kwdxgatndj - lymeyvzfel) View more | - | 23 Nov 2018 | ||
(Placebo) | dwonxfsgut(gvruawqthf) = lsxhczoutm qnydkwfhof (tcxpwhoyqv, nlvmumhrim - oncgayqqps) View more | ||||||
Not Applicable | - | Placebo | gmqbksivyb(ngzxcywkdo) = dauqotktrb afuhtmsukh (lbenuihkyj ) | - | 01 Jul 2006 | ||
gmqbksivyb(ngzxcywkdo) = ffmdttrdpe afuhtmsukh (lbenuihkyj ) |